Osimertinib-induced rapid regression of large metastatic tumor to the pituitary in a patient with lung adenocarcinoma
Tóm tắt
Metastatic nonsmall cell lung cancer (NSCLC) to the pituitary (NSCLC-PitM) is rare and often presents with visual field deficits. Surgical resection for the decompression of the optic apparatus has been the treatment of choice in such cases. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) approved for the treatment of patients with NSCLC with an epithelial growth factor receptor (EGFR) mutation though its role in the treatment of NSCLC-PitM that remains unclear. We present a case of NSCLC-PitM with optic chiasm compression and visual deficits that were successfully treated with osimertinib alone without surgical intervention.
A 43-year-old male presented with pleuritic chest pain, fatigue, and visual deficits found to have NSCLC and a sellar mass with suprasellar extension and optic chiasm compression. Visual field testing demonstrated associated visual field deficits. Molecular testing was positive for EGFR exon 19 deletion. The patient was started on osimertinib with complete resolution of pituitary lesion and visual deficits at 4 weeks.
Osimertinib is a third-generation EGFR-TKI that has demonstrated promising results among patients with metastatic EGFR-mutated NSCLC. While surgery is the mainstay of treatment in patients with a sellar mass, optic compression, and visual deficits, those with EGFR-mutated NSCLC-PitM may benefit from early initiation of such systemic therapies, rather than surgical intervention, with good ophthalmologic results.
Từ khóa
Tài liệu tham khảo
Adashek, 2018, EGFR T790M-positive lung adenocarcinoma metastases to the pituitary gland causing adrenal insufficiency: A case report, Case Rep Oncol Med, 2018, 2349021
Ayeni, 2015, Emerging agents and new mutations in EGFR-mutant lung cancer, Clin Cancer Res, 21, 3818, 10.1158/1078-0432.CCR-15-1211
Ballard, 2016, Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin Cancer Res, 22, 5130, 10.1158/1078-0432.CCR-16-0399
Fan, 2019, Complete resolution of sellar metastasis in a patient With NSCLC treated with osimertinib, J Endocr Soc, 3, 1887, 10.1210/js.2019-00217
Javanbakht, 2018, Pituitary metastasis: A rare condition, Endocr Connect, 7, 1049, 10.1530/EC-18-0338
Megyesi, 2019, P14.111 Successful treatment of extensive metastatic disease with successive use of two different EGF receptor antagonists: Case report and review of the literature, Neuro Oncol, 21, iii94, 10.1093/neuonc/noz126.346
Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, New Engl J Med, 376, 629, 10.1056/NEJMoa1612674
Okauchi, 2018, Paradoxical response to osimertinib therapy in a patient with T790M-mutated lung adenocarcinoma, Mol Clin Oncol, 8, 175
Rahmathulla, 2012, The molecular biology of brain metastasis, J Oncol, 2012, 723541, 10.1155/2012/723541
Shan, 2019, CMET-10, Intracranial solitary pituitary metastasis: The implications from five cases, Neuro Oncol, 21, vi53, 10.1093/neuonc/noz175.211